Associated tags: Research, Therapy, Kidney disease, IP Group, Laboratory, Sofinnova, AbbVie, DUB, University, Neurodegenerative disease, Dub, Enzyme, Fibrosis, Pharmaceutical industry, Patient, Health, Mitophagy, Mitochondrion, Drug discovery, Clinical Trials, Biotechnology, Pharmaceutical, Kidney, Safety
Locations: MISSION, UNITED KINGDOM, UNITED STATES OF AMERICA, MASSACHUSETTS, NEW YORK, PARKINSON, ENGLAND, UK
Retrieved on:
Thursday, December 14, 2023
Kidney,
Parkinson's disease,
Renal replacement therapy,
Food,
Therapy,
Acute kidney injury,
AKI,
US Foods,
IND,
Risk,
Disease,
Patient,
Mission,
FDA,
Mitophagy,
Pharmaceutical industry Dr Anker Lundemose, Chief Executive Officer of Mission Therapeutics, said: "The FDA's approval of our Phase II clinical study for our lead asset MTX652 marks a major milestone for Mission.
Key Points:
- Dr Anker Lundemose, Chief Executive Officer of Mission Therapeutics, said: "The FDA's approval of our Phase II clinical study for our lead asset MTX652 marks a major milestone for Mission.
- We now have two USP30 inhibitors advancing through clinical trials, MTX652 for acute kidney injury and MTX325 for Parkinson's Disease, validating our unique approach and the breadth of our assets."
- Dr Suhail Nurbhai, Chief Medical Officer of Mission Therapeutics, said: "Recent reports suggest that up to 50% of high-risk patients suffer acute kidney injury following heart surgery[i] [ii].
- We are delighted to have received this approval and look forward to starting this trial in 2024."
Retrieved on:
Thursday, December 14, 2023
Kidney,
Parkinson's disease,
Renal replacement therapy,
Food,
Therapy,
Acute kidney injury,
AKI,
US Foods,
IND,
Risk,
Disease,
Patient,
Mission,
FDA,
Mitophagy,
Pharmaceutical industry Dr Anker Lundemose, Chief Executive Officer of Mission Therapeutics, said: "The FDA's approval of our Phase II clinical study for our lead asset MTX652 marks a major milestone for Mission.
Key Points:
- Dr Anker Lundemose, Chief Executive Officer of Mission Therapeutics, said: "The FDA's approval of our Phase II clinical study for our lead asset MTX652 marks a major milestone for Mission.
- We now have two USP30 inhibitors advancing through clinical trials, MTX652 for acute kidney injury and MTX325 for Parkinson's Disease, validating our unique approach and the breadth of our assets."
- Dr Suhail Nurbhai, Chief Medical Officer of Mission Therapeutics, said: "Recent reports suggest that up to 50% of high-risk patients suffer acute kidney injury following heart surgery[i] [ii].
- We are delighted to have received this approval and look forward to starting this trial in 2024."
Retrieved on:
Monday, November 13, 2023
Parkinson's disease,
Research,
Alpha-synuclein,
Therapy,
Pathology,
PD,
Mouse,
Patient,
Mission,
Dopamine,
Ubiquitin,
Neuron,
Nature Communications,
University of Cambridge,
Harvard Medical School,
Mitochondrion,
Human,
Death,
Disability,
Biomarker,
Cell,
Mitophagy,
Pharmaceutical industry,
Palladium,
Disease CAMBRIDGE, England, Nov. 13, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces the publication of a peer-reviewed article titled 'Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's Disease (PD) mouse model' in the journal Nature Communications, which can be viewed here. The research was the result of collaborative work between Cambridge University, Harvard Medical School, and Mission Therapeutics.
Key Points:
- Mission Therapeutics is a global leader in discovering and developing innovative therapeutics that promote mitophagy.
- By inhibiting the enzyme USP30, Mission's experimental drug MTX325 helps promote mitochondrial quality control by increasing the removal of dysfunctional mitochondria.
- Dr Anker Lundemose, Chief Executive Officer at Mission Therapeutics, said: "The exciting findings of this Nature Communications paper are a tremendous boost to Mission's Parkinson's Disease programme.
- The Nature Communications paper outlines how Mission's drug MTX325 has potential as a novel, disease-modifying treatment for Parkinson's, by enhancing mitophagy and clearing dysfunctional mitochondria.
Retrieved on:
Monday, November 13, 2023
Parkinson's disease,
Research,
Alpha-synuclein,
Therapy,
Pathology,
PD,
Mouse,
Patient,
Mission,
Dopamine,
Ubiquitin,
Neuron,
Nature Communications,
University of Cambridge,
Harvard Medical School,
Mitochondrion,
Human,
Death,
Disability,
Biomarker,
Cell,
Mitophagy,
Pharmaceutical industry,
Palladium,
Disease CAMBRIDGE, England, Nov. 13, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces the publication of a peer-reviewed article titled 'Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's Disease (PD) mouse model' in the journal Nature Communications, which can be viewed here. The research was the result of collaborative work between Cambridge University, Harvard Medical School, and Mission Therapeutics.
Key Points:
- Mission Therapeutics is a global leader in discovering and developing innovative therapeutics that promote mitophagy.
- By inhibiting the enzyme USP30, Mission's experimental drug MTX325 helps promote mitochondrial quality control by increasing the removal of dysfunctional mitochondria.
- Dr Anker Lundemose, Chief Executive Officer at Mission Therapeutics, said: "The exciting findings of this Nature Communications paper are a tremendous boost to Mission's Parkinson's Disease programme.
- The Nature Communications paper outlines how Mission's drug MTX325 has potential as a novel, disease-modifying treatment for Parkinson's, by enhancing mitophagy and clearing dysfunctional mitochondria.
Retrieved on:
Thursday, November 2, 2023
Kidney,
Mitophagy,
Trial of the century,
Mission,
Mitochondrion,
Therapy,
Treatment,
DUB,
Acute kidney injury,
AKI,
Society,
Risk,
Master of Science,
Pharmacology,
Nephrology,
Safety,
Patient,
American Society of Nephrology,
MS,
Simulation,
Pharmaceutical industry CAMBRIDGE, England, Nov. 2, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology's Kidney Week in Philadelphia, from 2-5 November 2023.
Key Points:
- CAMBRIDGE, England, Nov. 2, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology's Kidney Week in Philadelphia, from 2-5 November 2023.
- Mission Therapeutics is a world leader in discovering and developing novel therapeutics which promote the removal of dysfunctional mitochondria to maintain cell health and function.
- The American Society of Nephrology is a major organization working toward a goal of a world without kidney diseases and we are excited to have the opportunity to share our progress at this important conference.
- A Phase II trial of MTX652 in patients at risk of acute kidney injury following cardiac surgery is planned to start in Q1 2024.
Retrieved on:
Thursday, November 2, 2023
Kidney,
Mitophagy,
Trial of the century,
Mission,
Mitochondrion,
Therapy,
Treatment,
DUB,
Acute kidney injury,
AKI,
Society,
Risk,
Master of Science,
Pharmacology,
Nephrology,
Safety,
Patient,
American Society of Nephrology,
MS,
Simulation,
Pharmaceutical industry CAMBRIDGE, England, Nov. 2, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology's Kidney Week in Philadelphia, from 2-5 November 2023.
Key Points:
- CAMBRIDGE, England, Nov. 2, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology's Kidney Week in Philadelphia, from 2-5 November 2023.
- Mission Therapeutics is a world leader in discovering and developing novel therapeutics which promote the removal of dysfunctional mitochondria to maintain cell health and function.
- The American Society of Nephrology is a major organization working toward a goal of a world without kidney diseases and we are excited to have the opportunity to share our progress at this important conference.
- A Phase II trial of MTX652 in patients at risk of acute kidney injury following cardiac surgery is planned to start in Q1 2024.
Retrieved on:
Tuesday, October 10, 2023
The Michael J. Fox Foundation,
Mitochondrial disease,
Research,
Biology,
Mitochondrion,
Therapy,
Neuron,
PINK1,
MJFF,
Protein,
DUB,
PD,
Mitophagy,
CNS,
Parkinson's disease,
Conference,
Patient,
Parkinson,
Pharmaceutical industry,
Disease Fox Foundation's Parkinson's Disease Therapeutics Conference on October 19, 2023, in New York.
Key Points:
- Fox Foundation's Parkinson's Disease Therapeutics Conference on October 19, 2023, in New York.
- Fox Foundation (MJFF) is dedicated to accelerating a cure for Parkinson's Disease and improved therapies for those living with the condition today.
- A major unmet need for Parkinson's Disease patients is a treatment that slows or prevents the progression of disease.
- Mission Therapeutics is currently developing two DUB inhibitors: MTX325 (targeting the CNS) and MTX652 (peripheral) which can potentially be used to treat any disease driven by mitochondrial dysfunction.
Retrieved on:
Tuesday, October 10, 2023
The Michael J. Fox Foundation,
Mitochondrial disease,
Research,
Biology,
Mitochondrion,
Therapy,
Neuron,
PINK1,
MJFF,
Protein,
DUB,
PD,
Mitophagy,
CNS,
Parkinson's disease,
Conference,
Patient,
Parkinson,
Pharmaceutical industry,
Disease Fox Foundation's Parkinson's Disease Therapeutics Conference on October 19, 2023, in New York.
Key Points:
- Fox Foundation's Parkinson's Disease Therapeutics Conference on October 19, 2023, in New York.
- Fox Foundation (MJFF) is dedicated to accelerating a cure for Parkinson's Disease and improved therapies for those living with the condition today.
- A major unmet need for Parkinson's Disease patients is a treatment that slows or prevents the progression of disease.
- Mission Therapeutics is currently developing two DUB inhibitors: MTX325 (targeting the CNS) and MTX652 (peripheral) which can potentially be used to treat any disease driven by mitochondrial dysfunction.
Retrieved on:
Thursday, January 5, 2023
Biotechnology,
Health,
Pharmaceutical,
Clinical Trials,
Cardiology,
Clinical trial,
Pharmacokinetics,
CMO,
Drug discovery,
Therapy,
Dub,
Muscle,
Optimism,
Enzyme,
Patient,
Safety,
Principal,
Pharmaceutical industry,
Medical device Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), today announced the successful completion of its first Phase I clinical assessment for lead USP30 DUB inhibitor, MTX652.
Key Points:
- Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), today announced the successful completion of its first Phase I clinical assessment for lead USP30 DUB inhibitor, MTX652.
- The Phase I First Time In Human (FTIH) study commenced in May 2022, following clinical trial approval in March .
- Involving over 80 healthy volunteers, the study was led by Principal Investigator Dr Annelize Koch, Senior Medical Director at Simbec-Orion.
- Dr Suhail Nurbhai, CMO of Mission Therapeutics commented:
“We are delighted with the successful completion of our first Phase I clinical assessment.
Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), announces that CEO, Dr Anker Lundemose, will present at the upcoming J.P Morgan Healthcare Conference .
Key Points:
- Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), announces that CEO, Dr Anker Lundemose, will present at the upcoming J.P Morgan Healthcare Conference .
- Mission Therapeutics’ presentation will take place at 5pm Wednesday January 11, 2023 in the Golden Gate Room at the Westin St Francis Hotel.
- The event, which will take place in San Francisco on 9-12 Jan 2023, is the largest healthcare investment symposium in the industry, and aims to connect global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
- If you would like to meet up with Anker and the team, please contact [email protected] .
